The Grupo Español de Linfomas y Trasplantes de M edula Osea International Prognostic Index (GELTAMO-IPI) stratifies four risk groups in diffuse large B cell lymphoma (DLBCL) patients treated with immunochaemotherapy: low (LR), low-intermediate (LIR), high-intermediate (HIR), and high (HR). The present study explores the effect of GELTAMO-IPI in the DLBCL subtypes defined by the immunohistochaemistry-based Hans algorithm, Germinal Centre B (GCB) and non-GCB. A multivariate Cox regression model including GELTAMO-IPI risk groups, cell of origin (COO) subtypes and their product was developed to evaluate interaction between the two variables. The COO subtype was available in 839 patients (380 GCB; 459 non-GCB) and both the GELTAMO-IPI and the COO subtype in 780 (353 GCB; 427 non-GCB). There were no differences in 5-year overall survival (OS) between the two subtypes. The Cox model revealed interaction between the GELTAMO-IPI risk groups and the COO subtypes (P = 0Á005), indicating that GELTAMO-IPI has a different effect in the two subtypes. Three risk groups were stratified in both COO subtypes: in the GCB subtype, LR, LIR and the combined HIR+HR had 5-year OS of 100%, 75% and 52%, respectively. In the non-GCB subtype, LR, the combined LIR+HIR and HR had a 5-year OS of, 97%, 82% and 35% respectively. GELTAMO-IPI identifies a genuine poor outcome group of patients in the DLBCL non-GCB subtype.
Introduction
The Grupo Español de Linfomas y Trasplantes de M edula Osea International Prognostic Index (GELTAMO-IPI) was recently developed to aid the prognosis of diffuse large B cell lymphoma (DLBCL) treated with immunochemotherapy (Montalban et al, 2017) . It has proved to have better prognostic efficacy than the National Comprehensive Cancer Network (NCCN)-IPI (Zhou et al, 2014; Montalban et al, 2017) , with the additional advantages of being able to identify a genuine high-risk group, and of not being influenced by the primary extranodal presentation or the use of a more intense treatment than R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone). Its prognostic effect has been validated in an independent series of DLBCL . The variables in GELTAMO-IPI and their statistical weight were: age (<65 years, 0 points; ≥65-79 years, 1 point; ≥80 years, 2 points); Eastern Cooperative Oncology Group performance score (0-1, 0 points; 2, 1 point; ≥2, 2 points); increased lactate dehydrogenase, increased b2-microglobulin and stage IV, one point each. The combination of these factors distinguished four risk groups: low risk (LR, 0 points), lowintermediate risk (LIR, (1) (2) (3) , high-intermediate risk (HIR, 4 points) and high risk (HR, ≥5 points), with 5-year overall survival (OS) of 93%, 79%, 66% and 39%, respectively.
On the other hand, gene expression profiling (GEP) has enabled three subtypes of DLBCL to be identified, on the basis of the tumour's apparent cell of origin (COO): germinal centre B cell-like (GCB), activated B-cell-like, and unclassified cases. These subtypes, GCB and non-GCB (activated and unclassified) DLBCL, seem to have different behaviours and prognoses, with different mechanisms and pathways that open up the opportunity to use therapies targeted to some specific key points (Alizadeh et al, 2000; Rosenwald et al, 2002) . Despite its theoretical attractiveness, it is not possible to use GEP routinely in standard clinical practice, and to overcome this drawback, the surrogate use of algorithms based on the immunohistochemical (IHC) expression of markers has been suggested as a way of reproducing the GEP classification. The Hans (Hans et al, 2004) , Choi (Visco et al, 2013) and ViscoYoung (Visco et al, 2012) algorithms are the most commonly used; although their efficacy is still controversial, in our experience with a series of 297 patients, all three were able to classify two groups of DLBCL with different outcomes (BatlleLopez et al, 2016) . The present study explores the prognostic effect of GELTAMO-IPI in the GCB and non-GCB subtypes of DLBCL treated with immunochemotherapy as identified by the Hans IHC algorithm.
Methods
The study was based on the original GELTAMO-IPI series, which comprised 1848 patients with de novo DLBCL from the GELTAMO network from institutions throughout Spain, who were treated with immunotherapy, R-CHOP or more intensive treatments (Montalban et al, 2017) . The histological diagnosis of DLBCL was performed by local pathologists using the initial diagnostic biopsies. COO was determined by means of the Hans algorithm, which uses the IHC expression of three markers (CD10, BCL6 and MUM1) (Hans et al, 2004) in paraffin-embedded samples. COO subtyping was accepted as stated in the pathology report of the diagnostic biopsy by the local pathologist; the result was accepted only when strictly defined as GCB or non-GCB; to avoid bias, type III/unclassifiable group was not included in the study. There was no central review or further interpretation of the markers in the original report. The patients contributed by participant centres included in the present study were selected only by the availability of COO classification and had no other characteristics that might have biased the selection.
To evaluate the presence of an interaction between GEL-TAMO-IPI grouping (LR, LIR, HIR, HR) and COO subtype (GCB, non-GCB) a multivariate Cox regression model for OS was developed that included these two variables and their product. All survival curves were obtained by the Kaplan- Meier method and compared using the log-rank test. Values of P < 0Á05 were considered statistically significant in all analyses. Statistical analyses were carried out with Stata 14Á0 (StataCorp LP, College Station, TX, USA).
Results
IHC data to evaluate the Hans algorithm for the classification of the COO subtype (GCB versus non-GCB) were available for 839 of the 1848 patients: 380 were classified as GCB and 459 were found to be non-GCB. The general clinical characteristics of the patients in the GCB and non-GCB subtypes and those of the original GELTAMO-IPI series (Montalban et al, 2017) are shown in Table I . There were no substantial differences among the clinical features in the two COO subtypes. There was no significant difference in 5-year OS between the GCB and non-GCB patients (76% and 78%, respectively; P = 0Á904) (Fig 1) . The general features of the patients with available COO information against those without are shown in Table S1 .
Complete data for determining both the GELTAMO-IPI risk group and the COO subtype were available from 353 GCB and 427 non-GCB cases, giving a final series of 780 patients. The distribution of these patients across the GELTAMO-IPI risk groups was: LR, 72 patients (9Á2%); LIR, 464 (59Á5%); HIR, 127 (16Á3%); and HR, 117 (15%). The 5-year OS was 98%, 79%, 67% and 41%, respectively, the differences being significant (P < 0Á001) overall and for pair-wise comparisons between groups ( Figure S1 ); the distribution and survival of the groups were similar to those in the original GELTAMO-IPI series of 1672 cases (Montalban et al, 2017 ).
The Cox model revealed an interaction between GEL-TAMO-IPI risk group and COO subtype (P = 0Á005) ( Table II) , indicating that GELTAMO-IPI has a different prognostic effect for the two COO subtypes. In the GCB subtype, the risk group distribution of patients was 34 (9Á6%) in LR, 221 (62Á6%) in LIR, 53 (15Á0%) in HIR, and 45 (12Á8%) in HR, with a 5-year OS of 100%, 75%, 53% and 51%, respectively. The overall differences in 5-year OS were significant (P < 0Á001), as was that between LR and LIR (P = 0Á008), but not that between HIR and HR (53% and 51%, P = 0Á81). Combining the HIR and HR groups to give a single group (HIR+HR) of 198 patients, with 5-year OS of 52%, produced significant differences from LR (P < 0Á001) and LIR (P = 0Á001) (Table III , Fig 2A) . The combination of the HIR and HR groups into a unique high-grade group therefore gives rise to three significantly distinct groups (Fig 3A) . The non-GCB subtype included 38 (8Á9%), 243 (56Á9%), 74 (17Á3%) and 72 (16Á9%) patients in the LI, LIR, HIR, and HR risk groups, with 5-year OS of 97%, 83%, 77% and 35%, respectively (Table III, Fig 2B) . The global difference in 5-year OS was significant (P < 0Á001), as was that between LR and LIR (P = 0Á012). Although the two intermediate groups, LIR and HIR, had a similar 5-year OS (P = 0Á258), there was a significant difference between the LR and the combined LIR+HIR groups (317 patients, 5-year OS of 82%; P = 0Á005) and between the LIR+HIR and HR groups (P < 0Á001), also resulting in a three-group stratification (Fig 3B) . A significantly Table I . General features of the DLBCL patients in the present study and the original GELTAMO series (Montalban et al, 2017) according to GCB/non-GCB subtype.
Cohort characteristics* GCB (n = 380) Non-GCB (n = 459) GELTAMO (n = 1848) 
Discussion
In the present series the GELTAMO-IPI stratified significant risk groups whereas there was no difference in the 5-year OS of GCB and non-GCB DLBCL subtypes, as identified by the Hans IHC algorithm. Multivariate Cox regression model demonstrated an interaction between the IHC COO subtype and GELTAMO IPI risk group: IHC COO subtyping did not predict mortality, but modified the predictor effect of GEL-TAMO-IPI (Figs 2A, 3A and Table II) . In both subtypes, GELTAMO-IPI identified a similar small low-risk group (involving around 9% of patients) with a 5-year OS of 100% and 97% in GCB and non-GCB respectively, a large intermediate-risk group comprising around 75% of patients, with a 5-year OS between 75% (GCB subtype) and 82% (non-GCB subtype), and a small higher-risk group, which exhibited the greatest difference: in the GCB subtype, comprising 12Á8% of patients, the 5-year OS was 52%, whereas the non-GCB subtype included a rather higher proportion of patients in the HR group (16Á7%) with a much poorer 5-year OS of 35%.
The similar outcome of the two COO subtypes in the present study was not coincident with our previous results from a series of 297 patients (Batlle-Lopez et al, 2016) where there was centralized and homogeneous ICH review, adding to the controversy regarding the genuine prognostic efficacy of the ICH-based COO stratification and its potential use in everyday practice. The obvious first issue with the present study is the lack of homogeneity, accuracy or reproducibility in the interpretation of the IHC findings in the different local pathology laboratories that performed this study that may have compromised the results. This cannot be excluded as there was no central review of the IHC data and is a limitation of the study. This is certainly an expected inconvenience in a large retrospective and multicentre study but, on the other hand, the present series has the advantage that is quite a large study (780 patients) of non-selected DLBCL treated with immunochemotherapy, R-CHOP or more intense therapy, and represents the outcome and the practical problems of diagnosis and subtype classification of DLBCL as they occur in a real life, non-trial setting.
The different outcomes of the DLBCL subtypes classified by COO has been based upon the results obtained from retrospective GEP studies (Alizadeh et al, 2000; Rosenwald et al, 2002) . This original approach cannot be used in routine practice for many reasons, including technical complexity, the requirement for frozen tissue and its high cost. To simplify methods, GEP has been carried out with a limited set of genes: in the Lymphoma/Leukaemia Molecular Profiling Project, the Lymph2Cx Nano-string assay GEP, including 20 genes in paraffin-embedded tissue in patients with DLBCL, was able to consistently assign COO subtypes (Scott et al, 2014) , and identified groups with different outcomes in a series of patients treated with R-CHOP, independently of the IPI score. In the GOYA prospective study comparing DLBCL treated with CHOP plus either rituximab or obinutuzumab, COO classification was based on GEP using a different nanostring assay and patients with the GCB subtype had a better outcome than those with the non-GCB subtypes, irrespective of the treatment arm (Vitolo et al, 2017) . The prospective REMODL-B study uses messenger RNA for GEP with an algorithm based on 20 genes, performed in paraffinembedded samples, with the aim of classifying patients as GCB or non-GCB at diagnosis, before starting the second cycle of treatment, and then randomizing to evaluate the effect of adding bortezomib to R-CHOP in the two subtypes (Davies et al, 2017) ; the 30-month progression-free survival of GCB patients treated with bortezomib/R-CHOP (75%) and R-CHOP (72%) and those of non-GCB treated with bortezomib/R-CHOP (71Á5%) or R-CHOP (64%) were not significantly different. Although it is not possible to compare the studies directly, these results are not dissimilar to the respective 5-year OS of 78% and 76% of the GCB and non-GCB subtypes in the present study.
To overcome these technical difficulties, COO subtyping has been done by the surrogate use of IHC algorithms. This is an easier and more accessible technique, but its reproducibility and accuracy are controversial. Some studies have confirmed its predictive value using the Hans, Choi and Visco-Young algorithms (Meyer et al, 2011; Batlle-Lopez et al, 2016) , but others (Ott et al, 2010) and a meta-analysis (Read et al, 2014) were unable to confirm this. In the prospective RICOVER-60 study (Ott et al, 2010) Hans algorithm-based subtyping did not discriminate prognostic groups on the basis of either OS or event-free survival, and neither did a prospective British study comparing CHOP14 and CHOP21 (Cunningham et al, 2013) . Good concordance (86%-87%) of the Choi, Hans and Tally algorithms with the GEP has been reported (Meyer et al, 2011) , but not confirmed (Gutierrez-Garcia et al, 2011). These discrepancies have been attributed to many factors: lack of reproducibility, technical shortcomings and differences in the interpretation of the staining results, and also to the fact that IHC algorithms cannot identify the type III/unclassifiable subtype and indiscriminately assign those cases to either GCB or non-GCB subtypes. Even when the technical problems are reasonably well overcome by using standardized staining and scoring, as in the case of the RICOVER-60 trial (Ott et al, 2010) , no survival difference between the two subtypes has been observed. All these discrepancies and controversial results question the real role of ICH in separating prognostic groups o DLBCL and its use in the everyday practice. The COO and IPI score were independent predictors in the studies using GEP (Rosenwald et al, 2002; Scott et al, 2015) .
Conversely, in the present study IHC COO subtype and GEL-TAMO-IPI interacted and showed that the subtyping, although not in itself a predictor of mortality, influenced the prognostic effect of GELTAMO-IPI. Despite the fact that COO classification did not result in different outcomes, the identification of a group with a very poor prognosis defined by HR GELTAMO-IPI and non-GCB COO subtype with only 35% of 5-year OS is of great importance, because the adequate treatment of patients with this aggressive non-GCB subtype is a clearly unmet need. GELTAMO-IPI can identify these very high-risk non-GCB patients, but cannot explain their worse outcome. It may depend on biological factors, such as the presence of MYC and/or BCL2 overexpression (as translocations of these genes are unusual in the non-GCB subtype) or other cytogenetics or molecular abnormalities, but we currently have no data available with which to settle this matter.
In conclusion, in this real-life study of a large population of DLBCL patients treated with immunochemotherapy, the combination of COO classification with the IHC-based Hans algorithm did not distinguish subtypes with different survival Table III . GELTAMO risk group distribution and 5-year OS in GCB and non-GCB subtypes A. germinal centre B (GCB) subtype: Global comparison, P < 0Á001; LR vs. LIR, P = 0Á008; LIR vs. HIR and HR, P < 0Á001; HIR vs. HR, P = not significant (n.s.) B. Non-GCB subtype: Global comparison, P < 0Á001; LR vs. LIR, P = 0Á012; LIR vs. HIR, P = n.s.; HR vs. HIR, P < 0Á001.
rates. GELTAMO-IPI can stratify three significant risk groups in both subtypes and is able to positively identify a genuine high-risk group in the non-GCB type. This prognostic stratification in the DLBCL COO subtypes using simple clinical factors, as included in GELTAMO-IPI, represents an easy and practical prognostic tool for use in clinical practice.
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